Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
about
Ebola virus diseaseCurrent Landscape of Antiviral Drug DiscoveryAddressing Therapeutic Options for Ebola Virus Infection in Current and Future OutbreaksPre-symptomatic diagnosis and treatment of filovirus diseasesApproved Antiviral Drugs over the Past 50 YearsCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusMolecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine TriphosphateExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaA response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic responseEbola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.Favipiravir: a new medication for the Ebola virus disease pandemic.Influenza antivirals currently in late-phase clinical trial.Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome VirusTreatment of ebola virus disease.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran.Ebola virus infection: what should be known?Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreakAntiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.Improving attrition rates in Ebola virus drug discovery.Novel Small Molecule Entry Inhibitors of Ebola Virus.Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Ebola Virus Infection: Overview and Update on Prevention and Treatment.Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever virusesEfficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.Potential and emerging treatment options for Ebola virus disease.Ebola virus disease: societal challenges and new treatments.Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Development of Small-Molecule Antivirals for Ebola.Clinical Evaluation of Ebola Virus Disease Therapeutics.Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses.Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.Discovering Drugs for the Treatment of Ebola Virus.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
P2860
Q24563097-07E60CB5-9441-4608-9DDC-66EA781B4382Q26766639-237AC8C3-F75A-4792-B6C5-9A970240DA80Q26801423-86670C69-84E8-4A73-AFAC-EA0293E42629Q26823831-4111CB3C-7E5D-4A23-9B93-C6D800E130D1Q27755387-BA8B705D-F6A8-4159-8047-439CC19C5C63Q28084005-D713E0F8-A044-48BA-8640-026D8C84F295Q28548547-834A54FF-24BD-4EE1-BA02-02412842A2BAQ28550455-267F0BD2-0117-4173-8FEC-906DE5703286Q30196960-741B7383-046E-475C-8078-EE5E8D66D1D0Q30251949-DCE28CEE-50B2-4787-986B-D8B025BB0F21Q30252022-451D1305-4D8C-40EF-91D0-91C72D6DD1ECQ30370190-37D0B214-DC42-4F64-B3EF-6063C2E2834FQ30398099-F2095F17-A4E9-4B5A-8893-47C841A0C52CQ33433096-AB78E1E6-E47A-4287-8FA6-A097037DEAF3Q34460182-39CDB1C1-491D-41D8-B9A2-B416622C7D0CQ34463780-94DBF3E8-B75D-4D21-8682-16E901441D21Q34516555-10F87C76-8E85-4BC6-B0B1-79A77D827781Q34551305-9A783744-C3A6-4DC7-958F-E48DA3573709Q34686400-63A7D2AB-8B83-40DE-AC6C-8794652BD00CQ35598919-6DFA4FCF-6878-448E-87BF-94757881A700Q35605579-B62F97BB-93AF-4884-B0DC-FD32BBA8A068Q35678774-1DAB9086-0C73-44CC-A7FA-79404582E3B6Q35709878-71660E38-16A3-453D-991A-0C6994A6B112Q35952190-A6E81819-4773-485C-9ACE-1C58F5EBE0D5Q36146469-4DA86661-3775-470B-B9CF-7A104EE750D4Q36288297-141E8A70-A128-43A3-845B-38B68C9AC228Q36363253-601E9BB9-B140-467A-8C8C-810129D9A1ECQ36494323-2CA440C4-DF57-4BD0-AF30-802C2C20E5B1Q36705853-1688955C-BFF2-4734-A55B-EC4025C6DA5AQ37203766-E23E5D12-B73D-4F63-A25F-53EB09C25346Q37538706-57365B91-16B2-4F5F-B9A0-9CA480A0CE02Q38270149-F895742F-5125-4B41-9D0A-D2336478CC13Q38388679-80406398-7872-4B8A-A82D-55D0B3D23E54Q38524949-971B04F1-2F2E-4C4D-9EB2-DF6CCDCFA8DEQ38546746-4AF07F62-4D46-428E-91AC-A5C397D3F299Q38617605-77CE3D0A-F676-47ED-A6BE-BEA2F36B45BEQ38766728-F22F978A-8DC4-490F-A1D1-ECC430883FF7Q38878840-33327BBE-940C-42D1-9483-FF14F13FD45FQ40039706-379089AA-D6FF-4471-8A46-EA9DC5F4F232Q40044875-E0A147A6-947F-433F-B75A-47AC89400C33
P2860
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Post-exposure efficacy of oral ...... us infection in a mouse model.
@ast
Post-exposure efficacy of oral ...... us infection in a mouse model.
@en
Post-exposure efficacy of oral T-705
@nl
type
label
Post-exposure efficacy of oral ...... us infection in a mouse model.
@ast
Post-exposure efficacy of oral ...... us infection in a mouse model.
@en
Post-exposure efficacy of oral T-705
@nl
prefLabel
Post-exposure efficacy of oral ...... us infection in a mouse model.
@ast
Post-exposure efficacy of oral ...... us infection in a mouse model.
@en
Post-exposure efficacy of oral T-705
@nl
P2093
P1433
P1476
Post-exposure efficacy of oral ...... us infection in a mouse model.
@en
P2093
Jackie A Steward
Lin S Eastaugh
Mark S Lever
Michelle Nelson
Robert P Lenk
Sophie J Smither
P304
P356
10.1016/J.ANTIVIRAL.2014.01.012
P577
2014-01-24T00:00:00Z